A New Approach to Treating Lupus & Sjögren’s

Home Diseases

Listen to the LFA podcast with Dr. Posada describing Resolve’s phase 2 SLE study

About Us

Resolve Therapeutics is pioneering first-in-class compounds for Systemic Lupus Erythematosus (SLE; “lupus”) and primary Sjögren’s syndrome (pSS). Our lead product candidate, RSLV-132, has the potential to prevent the inflammation that causes the debilitating symptoms of autoimmune diseases.

Our Novel Nuclease Platform

Resolve is developing a novel treatment to remove pro-inflammatory RNA molecules from the blood of patients with autoimmune diseases, including lupus and Sjögren’s. This therapeutic approach is supported by two decades of research validating that RNA held in circulation leads to chronic inflammation. By leveraging RNase, a safe molecule already found in blood, RSLV-132 digests RNA without being immunogenic or immunosuppressive, unlike many molecules currently in development for autoimmune diseases.

The Unmet Medical Need in  Lupus and Sjögren’s Syndrome

Lupus and Sjögren’s syndrome, which primarily affect women, occur when the immune system attacks its own organs. There is no cure for lupus, and no approved therapy available for Sjögren’s syndrome. Historically, these diseases have been under-researched and under-funded. Resolve’s first-in-class biologic has the potential to meet this critical unmet medical need in women’s health.

Btn Lupus
Btn Sjogrens

Btn Lupus OnBtn Sjogrens On